ES2169046T3 - Analogo de prostaglandina para el tratamiento de la osteoporosis. - Google Patents

Analogo de prostaglandina para el tratamiento de la osteoporosis.

Info

Publication number
ES2169046T3
ES2169046T3 ES93921469T ES93921469T ES2169046T3 ES 2169046 T3 ES2169046 T3 ES 2169046T3 ES 93921469 T ES93921469 T ES 93921469T ES 93921469 T ES93921469 T ES 93921469T ES 2169046 T3 ES2169046 T3 ES 2169046T3
Authority
ES
Spain
Prior art keywords
osteoporosis
prostaglandine
analog
treatment
prostaglandins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93921469T
Other languages
English (en)
Inventor
Peter C Tyler
Robert N Young
Gideon A Rodan
Rejean Ruel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Merck and Co Inc
Original Assignee
Merck Frosst Canada and Co
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada and Co, Merck and Co Inc filed Critical Merck Frosst Canada and Co
Application granted granted Critical
Publication of ES2169046T3 publication Critical patent/ES2169046T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5537—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

EL INVENTO SE REFIERE A UN COMPUESTO DE PROSTAGLANDINABIFOSFONATO DE FORMULA (I) Y SUS SALES FARMACEUTICAMENTE ACEPTABLES. LOS COMPUESTOS REFERIDOS SON EFECTIVOS COMO AGENTES DE LIBERACION DE PROSTAGLANDINAS PARA TRATAR OSTEOPOROSIS Y ENFERMEDADES SIMILARES DE HUESOS. ESTOS COMPUESTOS TAMBIEN LIBERAN SIMULTANEAMENTE UN BIFOSFONATO QUE INHIBE LA RESORCION OSEA Y LIBERA PROSTAGLANDINAS QUE INCREMENTAN LA FORMACION OSEA IN VIVO.
ES93921469T 1992-09-11 1993-09-09 Analogo de prostaglandina para el tratamiento de la osteoporosis. Expired - Lifetime ES2169046T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/944,149 US5409911A (en) 1992-09-11 1992-09-11 Prostaglandin analog for treating osteoporosis

Publications (1)

Publication Number Publication Date
ES2169046T3 true ES2169046T3 (es) 2002-07-01

Family

ID=25480889

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93921469T Expired - Lifetime ES2169046T3 (es) 1992-09-11 1993-09-09 Analogo de prostaglandina para el tratamiento de la osteoporosis.

Country Status (9)

Country Link
US (1) US5409911A (es)
EP (1) EP0662075B1 (es)
JP (1) JPH08501546A (es)
AT (1) ATE210643T1 (es)
AU (1) AU677597B2 (es)
CA (1) CA2144093A1 (es)
DE (1) DE69331326T2 (es)
ES (1) ES2169046T3 (es)
WO (1) WO1994006750A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914099A (en) * 1995-05-12 1999-06-22 Merck & Co., Inc. Prevention of tooth loss by the administration of alendronate or its salts
AU6148396A (en) * 1995-06-06 1996-12-24 Merck & Co., Inc. Disodium alendronate formulations
AU5973496A (en) * 1995-06-06 1996-12-24 Merck & Co., Inc. Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
US5935607A (en) * 1996-02-15 1999-08-10 Hadasit Medical Research Services And Development Company Ltd. Treatment of osteoporosis
US6303155B1 (en) 1996-02-15 2001-10-16 Hadasit Medical Research Services And Development Company, Ltd. Treatment of conditions associated with impairment in the level of the parathyroid hormone
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
AU4881697A (en) 1996-12-20 1998-07-17 Pfizer Inc. Prevention and treatment of skeletal disorder with EP2 receptor subtype se lective prostaglandin E2 agonists
HUP0004581A2 (hu) * 1997-09-09 2001-05-28 The Procter & Gamble Co. Eljárás csonttérfogat növelésére nem természetes előfordulású FP szelektív agonisták alkalmazásával
ATE270660T1 (de) * 1997-09-09 2004-07-15 Univ Duke Aromatische c16-c20-substituierte tetrahydro- prostaglandine verwendbar wie fp agoniste
EP1012137B1 (en) * 1997-09-09 2002-11-06 The Procter & Gamble Company Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
US6747055B1 (en) 1998-07-17 2004-06-08 The United States Of America As Represented By The Department Of Health And Human Services Water-soluble drugs and methods for their production
AU764603B2 (en) * 1998-07-17 2003-08-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Water-soluble drugs and methods for their production
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
US6121253A (en) * 1998-11-20 2000-09-19 Merck Frosst Canada & Co. Prostaglandin conjugates for treating or preventing bone disease
JP2002538122A (ja) * 1999-03-05 2002-11-12 ザ プロクター アンド ギャンブル カンパニー 天然に存在しないｆｐ選択的アゴニストおよび骨吸収抑制化合物を用いる骨体積の増加方法
AU766163B2 (en) 1999-03-05 2003-10-09 Duke University C16 unsaturated fp-selective prostaglandins analogs
AU3385900A (en) * 1999-03-05 2000-09-21 Procter & Gamble Company, The Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
DK1175433T3 (da) 1999-05-04 2005-09-19 Strakan Int Ltd Androgenglycosider og androgen aktivitet deraf
CA2308532C (en) * 1999-05-12 2005-11-29 Gador S.A. Use of bisphosphonates for the treatment of osteogenesis imperfecta
ES2202156T3 (es) * 1999-08-04 2004-04-01 Procter & Gamble Nuevos analogos de 2-descarboxi-2-fosfinico prostaglandina f.
EP1267888A4 (en) 2000-01-04 2005-12-28 Univ California USE OF LOW-DOSEED BISPHOSPHONATES FOR PREVENTING THE CALIBRATION OF HEART AND ARTERIES
WO2001051497A1 (en) * 2000-01-14 2001-07-19 Strakan Limited Novel bisphosphonates and uses thereof
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
CN100463910C (zh) * 2006-12-14 2009-02-25 西北工业大学 二膦酸盐衍生物的制备方法
US20100099640A1 (en) * 2007-05-04 2010-04-22 Joannes Geuns Tissue degeneration protection
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
CA2738045C (en) * 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
CA2828133A1 (en) 2011-02-24 2012-08-30 Ktb Tumorforschungsgesellschaft Mbh Bisphosphonate-prodrugs
CA2837261C (en) 2011-06-02 2020-12-15 CHINOIN Zrt. Novel processes for the preparation of prostaglandin amides
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
US10400000B2 (en) 2015-06-12 2019-09-03 Simon Fraser University Amide-linked EP4 agonist-bisphosphonate compounds and uses thereof
CN116716241A (zh) 2016-03-04 2023-09-08 莱兰斯坦福初级大学评议会 利用前列腺素e2进行肌肉再生的组合物和方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975404A (en) * 1971-05-04 1976-08-17 The Upjohn Company Bicyclic lactone intermediates
US3927197A (en) * 1974-04-19 1975-12-16 Pfizer Tertiary alcohol stabilized E-series prostaglandins
US4018892A (en) * 1975-08-06 1977-04-19 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4097601A (en) * 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US4171331A (en) * 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
ATE66608T1 (de) * 1984-04-30 1991-09-15 Procter & Gamble Ausruestung fuer die behandlung der osteoporose.
JPS6191137A (ja) * 1984-10-11 1986-05-09 Kao Corp 外用薬剤組成物
DE3519361A1 (de) * 1985-05-30 1986-12-04 Boehringer Ingelheim International GmbH, 6507 Ingelheim (gamma)-ifn als wirkstoff zur hemmung (verhinderung) von abbauprozessen im knochen
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
EP0341961A3 (en) * 1988-05-09 1990-06-20 Merck & Co. Inc. Polymalonic acids as boneaffinity agents
JPH0778024B2 (ja) * 1988-10-14 1995-08-23 藤沢薬品工業株式会社 医薬化合物とジホスホン酸誘導体の結合体を含有する医薬用製剤
JPH0759505B2 (ja) * 1988-11-17 1995-06-28 帝人株式会社 シクロペンテノン類を活性成分とする骨形成促進剤
US5071655A (en) * 1990-01-12 1991-12-10 Baylink David J Pharmaceutical combination for treatment of bone-wasting diseases
EP0496520A1 (en) * 1991-01-22 1992-07-29 Merck & Co. Inc. Novel bone acting agents
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation

Also Published As

Publication number Publication date
EP0662075A1 (en) 1995-07-12
DE69331326D1 (de) 2002-01-24
EP0662075B1 (en) 2001-12-12
WO1994006750A1 (en) 1994-03-31
EP0662075A4 (en) 1998-05-20
AU677597B2 (en) 1997-05-01
US5409911A (en) 1995-04-25
AU4855493A (en) 1994-04-12
JPH08501546A (ja) 1996-02-20
CA2144093A1 (en) 1994-03-31
DE69331326T2 (de) 2002-11-07
ATE210643T1 (de) 2001-12-15

Similar Documents

Publication Publication Date Title
ES2169046T3 (es) Analogo de prostaglandina para el tratamiento de la osteoporosis.
IL104109A0 (en) Pharmaceutical compositions containing aldenorate for treating periodontal diseases
DE60211935D1 (de) Alkandiol derivate zur behandlung von knochenkrankheiten
ES2191475T3 (es) Conjugados de prostaglandina para el tratamiento o prevencion de enfermedades oseas.
EA200000682A1 (ru) Новые ацилгуанидиновые производные в качестве ингибиторов резорбции костной ткани и антагонистов витронектиновых рецепторов
ES2165969T3 (es) Compuestos nitrogenados aromaticos condensados 5,5 aril-sustituidos como agentes antiinflamatorios.
HUP9901246A2 (hu) Növekedési hormon kiválasztását elősegítő vegyületek
EA200500088A1 (ru) Трициклические модуляторы ядерного рецептора стероидного гормона
ATE446758T1 (de) Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
MY146809A (en) Treatment and prevention of osteoporosis
CA2415228A1 (en) Treatment of bone diseases
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
AR003121A1 (es) Antagonistas del receptor de adhesión, procedimiento para prepararlos, composiciones farmacéuticas que los contienen y su empleo para preparar medicamentos y combatir enfermedades
NZ515541A (en) Pharmaceutical compositions comprising bisphosphonates to treat angiogenesis
EE9600191A (et) Püridüülbisfosfonaatide kasutamine terapeutiliste toimeainetena
PL371264A1 (en) Method for the treatment of bone disorders
BR0214293A (pt) Composto e métodos para tratar um paciente que tenha, ou de prevenir um paciente de adquirir, uma doença ou condição e para produzir um composto ou um sal ou éster farmaceuticamente aceitável do mesmo
EP0612246A4 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING GALLIUM COMPLEXES OF 3-HYDROXY-4-PYRONES.
BR0315293A (pt) Derivados de lactona para o tratamento de hiperparatireoidismo
TH21056A (th) การรักษาที่ประกอบกันสำหรับการยับยั้งการสูญเสียกระดูก

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 662075

Country of ref document: ES